Theravance Biopharma, Inc. (TBPH): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Older than the company's other figures. The latest EBITDA is for the year ended 2018-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report Depreciation & Amortization, which EBITDA is computed from, under the concepts TickerFacts maps.

-$235.59M

Year ended 2018-12-31

2012-12-31 EBITDA (USD) 2018-12-31

Period ended	EBITDA	Change YoY	Source filing
2018-12-31	-$235.59M	n/m	2021-02-26, From 2018-01-01
2017-12-31	-$256.10M	n/m	2020-02-27, From 2017-01-01
2016-12-31	-$177.35M	n/m	2019-02-28, From 2016-01-01
2015-12-31	-$178.91M	n/m	2018-02-28, From 2015-01-01
2014-12-31	-$229.26M	n/m	2017-03-01, From 2014-01-01
2013-12-31	-$153.63M	n/m	2016-03-11, From 2013-01-01
2012-12-31	-$6.32M	n/a	2015-03-13, From 2012-01-01